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resistant to infection than synthetic prostheses has been
suggested as an alternative. On the basis of excellent long-
term results reported by cardiac surgeons after cryopre-
served allograft replacement for the management of
infections of the ascending aorta,3,4 we decided in the
1990s to investigate cryopreserved arterial allografts in the
management of arterial infections. The aim of this
prospective, observational study was to evaluate the safety
and efficacy of cryopreserved arterial allograft reconstruc-
tion in the treatment of abdominal aortic infection (pri-
mary or prosthetic graft infection). The main variables
studied were patient survival, freedom from persistent or
recurrent infection, allograft patency, and avoidance of
major amputation.
PATIENTS AND METHODS
From April 1992 to March 2000, data from patients
with abdominal aortic infection (primary or prosthetic
graft infection) in our Department of Vascular and
Thoracic Surgery (Beaujon University Hospital, Clichy,
France) were prospectively collected. These data included
demographics, atherosclerotic risk factors, original proce-
dures, modes of presentation, indications for allograft
reconstruction, surgical details, perioperative morbidity,
and bacteriologic findings. The diagnosis of abdominal
aortic infection was made on the basis of clinical presenta-
Abdominal aortic infection remains a major surgical
challenge. Traditional surgical treatment of abdominal
aortic infection includes excision and drainage of infection
with oversewing of the infrarenal aorta and axillofemoral
bypass grafting. Although this treatment is considered a
“gold standard,” it still results in significant mortality and
morbidity rates related to aortic stump blowout and extra-
anatomic bypass graft (EAB) failure from thrombosis,
recurrent infection, or both.1 In situ reconstruction is an
alternative treatment in cases of aortic sepsis, because it
has a theoretically better long-term patency rate and spe-
cific complications related to the extra-anatomic strategy
can be avoided. However, in situ reconstruction with
prosthetic materials has a high risk of persistent or recur-
rent infection and related mortality and morbidity.2 As a
result, in situ replacement with a conduit that is more
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Purpose: This prospective, observational study determined the long-term outcome in patients with abdominal aortic
infection (primary or prosthetic graft) who were treated with simultaneous aortic/graft excision and cryopreserved
arterial allograft reconstruction.
Methods: From April 1992 to March 2000, patients with abdominal aortic infection underwent complete or partial exci-
sion of the infected aorta/prosthetic graft and cryopreserved arterial allograft reconstruction. Arterial allografts were
harvested from multiple organ donors and cryopreserved at –80°C without rate-controlled freezing. The patients 
were observed for survival, limb salvage, persistence and/or recurrence of infection, and allograft patency. The results
were calculated with life-table methods.
Results: During the 8-year study period, 28 consecutive patients (27 men, 1 woman; mean age, 64 years) underwent
treatment for abdominal aortic infection (23 graft infections, including 7 graft-enteric fistulas and 5 primary aortic
infections). Allograft reconstruction was performed as an emergency procedure in 13 patients (46%). The mean follow-
up period was 35.4 months (range, 6-101 months). The overall treatment-related mortality rate was 17.8% (17% for
graft infection, 20% for primary aortic infection). The overall 3-year survival was 67%. There was no early or late ampu-
tation. There was no persistent or recurrent infection, and none of the patients received long-term (> 3 months) antibi-
otic therapy. Reoperation for allograft revision, excision, or replacement was necessary in four patients (17%) who were
available for examination, with no reoperative perioperative death. The 3-year primary and secondary allograft patency
rates were 81% and 96%, respectively.
Conclusion: Our experience with cryopreserved arterial allograft in the management of abdominal aortic infection sug-
gests that this technique seems to be a useful option for treating one of the most dreaded vascular complications. (J
Vasc Surg 2001;34:616-22.)
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tion and computed tomographic scanning. Patients with
abdominal aortic infection underwent complete or partial
excision of the infected aorta or prosthetic graft, followed
by cryopreserved arterial allograft reconstruction. The
patients initially underwent treatment with broad-
spectrum intravenous antibiotics. Preoperative arteriogra-
phy of the aorta and lower extremities was routinely per-
formed when possible.
Surgical technique. Abdominal aortic mycotic
aneurysm and complete prosthetic graft infection were
approached through a midline incision and excised in their
entirety. Single-prosthetic graft limb infection was
approached through a retroperitoneal incision, and the
graft was partially excised. Bacteriologic culture tests were
performed on the periprosthetic fluid, the infected pros-
thetic graft, or the infected aorta, and wounds were care-
fully debrided. The arterial allografts were implanted with
polypropylene suture for proximal and distal anastomoses.
Before allograft reconstruction, any open wounds or
draining sinus tracts were isolated with adhesive sterile
dressings. End-to-side femoral anastomoses were made
through incisions at a distance from any infected areas.
The common femoral artery was the preferred choice for
the distal anastomosis when it was not involved with the
infection. Distal anastomoses were constructed to the pro-
funda or to the superficial femoral arteries beyond the
inguinal region through lateral incisions when necessary.
In patients with secondary aortoenteric fistulas, the bowel
defect was repaired with lateral closure or bowel resection.
Allograft reconstruction was covered with a pedicled
omentoplasty in all patients except those with single-
prosthetic graft limb infection. Retroperitoneal and
inguinal drainage was routinely used.
Arterial allograft. Harvesting, preservation, and
preparation of allografts have been described earlier.5,6
Arterial allografts (descending thoracic aorta, aortic bifur-
cation, iliac and femoral arteries) were carefully harvested
from brain-dead multiple organ donors. Informed consent
was given by the donor’s family, in accordance with French
law. Bacteriology and virology tests (human immunodefi-
ciency virus 1, 2; human T-lymphotrophic virus 1, 2;
hepatitis C virus; hepatitis B virus; cytomegalovirus) were
performed for all donors. After harvesting, arterial allo-
grafts were flushed with heparinized saline solution to
eliminate any residual intra-arterial blood and stored at
4°C in M199 medium (Gibco Laboratories, Gaithersburg,
Md) containing gentamycin (0.50 mg/mL) and ampho-
tericin B (0.25 mg/mL). The delay before freezing did not
exceed 18 hours in all cases. Allografts were permeated for
20 minutes at 4°C in M199 medium containing 12%
dimethylsulfoxide and subsequently frozen at –80°C with-
out rate-controlled freezing. The average storage duration
was 76 days (± 60.8 days). On request from the vascular
surgeon, the bag containing the artery was rapidly thawed
by means of immersion in water prewarmed to 37°C. Once
all the ice had melted, the allografts underwent successive
washouts in heparinized saline solution at room tempera-
ture. The final washout fluid was sampled for bacteriologic
culture. Because of the few available allografts, matching
blood compatibility between recipient and donor was not
possible in all cases. Twenty-two cryopreserved arterial
allografts (78%) were ABO compatible with the recipient;
six cryopreserved arterial allografts were mismatched.
None of the patients received immunosuppression therapy.
Postoperative management and follow-up exami-
nation. Intravenous antibiotics were administered for 2
weeks, and culture-determined oral antibiotics continued
to be administered for at least 6 weeks. All surviving
patients underwent arteriography with digital subtraction
before discharge from the hospital. After discharge, rou-
tine late follow-up included a clinical and duplex scanning
examination at 1 month and every 6 months thereafter.
Late computed tomographic scanning, arteriography, or
both were performed, depending on the results of duplex
scanning. Patients with underlying occlusive disease were
routinely prescribed daily low-dose aspirin (100 mg/d).
For the purposes of this report, the status of all survivors
was updated in September 2000. Patency, limb salvage
rate, and survival were determined with a standard life-
table analysis by means of the Kaplan-Meier method.
RESULTS
Patients and initial procedures. During the 8-year
study period, 28 consecutive patients (27 men, 1 woman;
mean age, 64 years; age range, 44-82 years) underwent
treatment for an abdominal aortic infection. These
included 5 mycotic aortic aneurysms, including 3 that were
ruptured (2 infrarenal, 1 juxtarenal), and 23 aortic pros-
thetic graft infections. Of the 23 patients with aortic pros-
thetic graft infections, 10 had prosthetic graft-enteric
Table I. Clinical presentation of the 23 patients with
infected aortic prosthetic graft
Events No.
Sepsis (fever, leukocytosis, and tachycardia) 10
Severe gastroduodenal bleeding 5
Groin abscess 14
Aortic false aneurysm 3
Femoral anastomotic rupture 3
Acute limb ischemia 3
Table II. Types of arterial allograft reconstructions in
28 patients
Reconstructions No.
Aortoaortic bypass grafting 6 (5 mycotic aneurysms)
Aortobi-iliac bypass grafting 1
Aortobifemoral bypass grafting 5
Aortounifemoral bypass grafting 2
Aortounifemoral and femorofemoral bypass grafting 4
Prosthetic graft limb—DFA 8
Prosthetic graft limb—SFA 2
DFA, Deep femoral artery; SFA, superficial femoral artery.
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fistulas/erosions and 13 had prosthetic graft infection
without bowel involvement. Of the 10 patients with bowel
involvement, 7 had a true fistula and 3 had a prosthetic
graft enteric erosion. Of the 13 patients with prosthetic
graft infection without bowel involvement, 10 had a single-
prosthetic graft limb infection. Seven of these 23 patients
(30%) with aortic prosthetic graft infections had initially
undergone surgery in our center; 16 patients (70%) were
referred to us after undergoing one or more operations
that were performed elsewhere. The initial operation had
been performed for aortoiliac occlusive disease in 20
patients (87%) and for abdominal aortic aneurysm disease
in three patients (13%). The mean interval from the aortic
graft insertion to the diagnosis of graft infection was 43
months (range, 1-168 months). A mean of 2.8 ± 2.1 oper-
ations (range, 1-10) had been performed before allograft
reconstruction. Configurations of the infected aortic grafts
were aortoaortic in 2 patients, aortobifemoral in 18 patients,
and aortounifemoral in 3 patients. Graft material was poly-
ester fiber (Dacron) in 22 patients and polytetrafluoroethyl-
ene (PTFE) in one patient.
Manifestation and preoperative diagnosis. The
clinical events in 23 patients with infected aortic prosthetic
graft are described in Table I. Because of acute bleeding (n
= 7), acute ischemia (n = 2), or both (n = 1) and ruptured
mycotic aortic aneurysm (n = 3), allograft aortic recon-
struction was performed as an emergency procedure in 13
patients (46%), whereas it was a planned procedure in 15
patients (54%).
Treatment and early outcome. The five patients with
a mycotic aortic aneurysm underwent complete excision of
the infected aorta, in situ aortoaortic allograft reconstruc-
tion, and coverage of the allograft with pedicled omento-
plasty. Additional procedures, including left nephrectomy,
reimplantation of the right renal artery in the allograft, and
ablation of spine orthopedic material, were performed in
one patient who had a ruptured juxtarenal mycotic
aneurysm. The 10 patients with single-prosthetic graft limb
infection underwent single-prosthetic graft limb removal
and prosthesis-femoral allograft reconstruction without
omentoplasty. The remaining 13 patients underwent com-
plete prosthetic graft removal and in situ aortoaortic 
allograft reconstruction (1 case), in situ aortobi-iliac allo-
graft reconstruction (1 case), in situ aortobifemoral allograft
reconstruction (5 cases), in situ aortounifemoral allograft
reconstruction (2 cases), or in situ aortounifemoral plus
femorofemoral allograft reconstruction (4 cases; Table II).
These 13 patients all underwent pedicled omentoplasty. In
patients with graft-enteric fistulas, the bowel defect was
repaired with lateral closure of the duodenum in 4 cases,
right colectomy for a perforated carcinoma of the cecum in
1 case, and ileum resection in 2 cases.
Bacteriologic culture results were positive for infection
in all cases (Table III). Infection was caused by a variety of
organisms, the most frequent being Staphylococcus aureus.
Five patients with prosthetic graft-enteric fistulas had mul-
tiple organisms from the graft on culture.
The perioperative mortality rate was 17.8% (5 of 28).
All five patients who died in this series were from the
group of 18 patients who underwent complete aortic or
graft excision (27.8%). The perioperative mortality rate
was 20% (1 of 5) in patients with mycotic aneurysm, 30%
(3 of 10) in patients with prosthetic graft-enteric fistu-
las/erosion, and 7.6% (1 of 13) in patients with prosthetic
graft infection without bowel involvement. There was no
perioperative death in the 10 patients with single-
prosthetic graft limb infection. Five patients died before
hospital discharge on postoperative days 2, 8, 28, 42, and
62. Death was caused by sepsis (2 patients), multisystem
organ failure (2 patients), and iatrogenic agranulocytosis
(1 patient). Of these 5 patients, 3 had required an emer-
gency procedure, 3 had a graft-enteric fistula with fecal
peritonitis caused by a perforated carcinoma of the cecum
in 1 case, 1 had a ruptured mycotic aneurysm, and 1 was
an 80-year-old patient with cachectic condition and severe
sepsis. Six of the 23 surviving patients (26%) had non–
allograft-related complications. These included transient
renal failure (2 patients), small bowel occlusion (1 patient),
delirium tremens (1 patient), mucous enteritis (1 patient),
and urinoma (1 patient). Normal patent allograft recon-
structions were demonstrated in all 23 surviving patients
by means of routine arteriography before hospital dis-
charge. The mean duration of hospitalization was 22 days
(± 10 days).
Late outcome. All surviving patients were followed
up except one who did not continue follow-up after 6
months. The mean follow-up period for surviving
patients was 35.4 months (range, 6-101 months). Five
patients died during later follow-up in postoperative
months 13, 14, 28, 41, and 55. None of the deaths were
related to treatment. Causes of later deaths were myocar-
dial infarction (n = 2), lung cancer (n = 1), rectum cancer
(n = 1), and cardiac rhythm disorders (n = 1). The cumu-
lative survival was 78% at 1 year and 67% at 3 years,
including the perioperative deaths (Fig 1). One patient
who underwent aortounifemoral plus femorofemoral
Table III. Organisms grown from infected prosthetic
graft or infected aorta in 28 patients
Organism No.
Mycotic aneurysm (n = 5)
Salmonella 2
Candida albicans 1
Staphylococcus aureus 2
Infected prosthetic graft (n = 23)
S aureus 13
Staphylococcus epidermidis 2
Enterococci 2
Streptococcus viridans 1
Enterobacter cloacae 1
Escherichia coli 4
Proteus mirabilis 1
Streptococcus anginosus 1
Streptococcus mitis 1
Streptococcus intermedius 1
allograft reconstruction for prosthetic graft enteric fistu-
las had femorofemoral allograft thrombosis 4 months
postoperatively. The femorofemoral allograft was totally
replaced with a PTFE graft, and the patient had an
uneventful recovery. This patient died of cardiac rhythm
disorders 37 months after the “redo” procedure, and he
had a patent infection-free graft at the time of death.
Limited aneurysmal deterioration of the cryopreserved
allograft occurred in three patients (2 prosthetic-femoral
allograft reconstructions, 1 femorofemoral allograft) in
postoperative months 14, 45, and 90. Two of these allo-
grafts were ABO compatible with the recipient, and one
allograft was mismatched. Only the aneurysmal part of
the allograft and 1 cm from both ends were removed and
replaced with a PTFE graft. In each case, more than half 
the original allograft and the two original anastomoses were
retained. These three patients were alive and infection 
free 78, 6, and 11 months after the “redo” procedure.
One patient had a distal extension (femoropopliteal
bypass grafting procedure with the saphenous vein) for
disabling claudication 26 months after aortounifemoral
plus cross femorofemoral allograft reconstruction. This
patient was still alive and was infection free 37 months
after the distal extension. Overall, reoperation for allo-
graft revision, excision, or replacement was necessary in 4
patients (17%), in 3 cases for limited aneurysmal deterio-
ration, and in 1 case for occlusion. The mean duration of
surgery was 130 minutes for the four “redo” procedures,
and the mean duration of hospitalization was 7 days (± 2
days). There was no early or late amputation in this series
(100% limb salvage rate). There was no persistent or
recurrent infection, and none of the patients received
long-term (> 3 months) or indefinite antibiotic therapy.
The 3-year primary and secondary allograft patency rates
were 81% and 96%, respectively (Figs 2 and 3).
DISCUSSION
Our long-term experience with cryopreserved arterial
allografts in the management of abdominal aortic infec-
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tion suggests that this technique is a useful option for
treating one of the most dreaded vascular complications.
The early mortality rate in our series was 17.8%, and
there were no late deaths or complications caused by per-
sistent or recurrent infection during a mean follow-up
period of 35.4 months. Furthermore, one death occurred
as a result of iatrogenic agranulocytosis in a patient who
underwent successful surgery for a ruptured mycotic aor-
tic aneurysm and who otherwise had an uneventful early
postoperative recovery and an intact allograft with no
signs of persistent infection at autopsy. Because 18 patients
(64%) in this series had life-threatening aortic infections
and 13 of these required emergency operations because of
acute bleeding, acute ischemia, or a ruptured mycotic aor-
tic aneurysm, we think that the mortality rate in this series
is within the range reported in recent series with conven-
tional methods.7-12
None of the patients in this series experienced persis-
tent or recurrent infection. Although one obvious concern
is whether a longer follow-up period will reveal recurrent
infection, the mean follow-up period of 35 months, with
all allografts observed for at least 6 months, is reassur-
ing.13 Furthermore, no reinfections occurred in any of the
four patients who required implantation of a new pros-
thetic graft. The high resistance to infection of allografts
in our series supports the results of experimental studies
and clinical results of allograft replacement in infected
fields.14-18 However, we cannot generalize that in situ
allograft replacement is safe for all types of infection.
Indeed, caution should be used when planning in situ allo-
graft replacement in patients with extensive infection and
gross purulence or highly virulent gram-negative organ-
isms. Thus, in four patients in this series who required
complete graft removal and aortobifemoral reconstruc-
tion, an aortounifemoral plus femorofemoral replacement
was performed after complete graft removal to avoid
placement of the allograft on one side of an extensive con-
taminated bed. Moreover, careful wound debridement,
the coverage of allografts with pedicled omentoplasty, and
Fig 1. Percent survival rates with life-table analysis. Error bars
represent SEM.
Fig 2. Primary patency rates with life-table analysis. Error bars
represent SEM.
the perioperative intravenous administration of appropri-
ate antibiotics were routinely performed and were impor-
tant factors for successfully eradicating infection in this
series.
Seventy-one percent (20 of 28) of the patients in this
series had severe underlying occlusive disease and were at
high risk of limb loss. Therefore, it is important to note
that there were no early or late amputations in our patients
and that the 3-year primary and secondary allograft
patency rates were 81% and 96%, respectively. Although
the heterogenicity of patients and the general diagnosis of
arterial graft infection make comparisons between series
quite difficult, we think that the outcomes of the long-
term follow-up in our series for patency, limb salvage, free-
dom from reinfection, and allograft-related morbidity
compare favorably with other recent series that used con-
ventional methods. Seeger et al11 reported an 11% ampu-
tation rate, and 35% of the patients available for follow-up
had EAB failure from thrombosis, infection, or both; one
patient had late aortic stump disruption. Yeager et al10
reported an 11.5% amputation rate; 27% of the patients
available for follow-up had EAB failure, and the overall
rate of freedom from graft failure was 68% at 3 years.
Sharp et al9 reported no early amputations. However,
although 19 (70%) aortic replacements were performed
for aneurysm disease, 33% of the patients available for 
follow-up had EAB failure. Furthermore, the 80%, 2-year
primary patency rate reported in this study was obviously
overestimated, because, to determine graft patency, they
counted each axillofemoral bypass graft limb as a separate
graft. Kuestner et al19 reported a 12.1% amputation rate;
46% of the patients available for follow-up had EAB failure
from thrombosis, infection, or both. Ricotta et al8
reported 32 patients treated for aortic graft infection,
eight with aortoenteric fistulas. Patients were treated by
means of partial removal with (8 patients) or without (4
patients) revascularization or total removal with (18
patients) or without (2 patients) revascularization.
Perioperative amputation, reoperation, and reinfection
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rates were 13%, 9%, and 6%, respectively. There was no
reduction in operative mortality and morbidity rates in
patients who underwent partial rather than total graft
excision. The opposite trend was observed, although this
was not statistically significant. Quinones-Baldrich et al12
reported an 18% early amputation rate, a 23% late ampu-
tation rate, and a 20% reinfection rate requiring second
operations. Primary and secondary patency rates at 3 years
were 43% and 65%, respectively. Overall, 78 operations,
including 35 thrombectomies, were performed in the
group of 30 survivors to treat EAB failure from thrombo-
sis, infection, or both. Abdominal aortic infection remains
a major surgical challenge, and at present, there is no one
unique treatment for all aortic graft infections. Clagett et
al20 and Nevelsteen et al21 reported the use of superficial
femoropopliteal vein for aortofemoral reconstruction in
infected fields. They both reported good results, with
postoperative mortality and early amputation rates of 10%
and 7%, and 5% and 7%, respectively. However, in Clagett
et al’s study, the mean operative time was 7.9 hours, and
postoperative morbidity occurred in 49% of the patients.
In Clagett et al’s study, only three of 41 patients had sec-
ondary aortoenteric fistulas, and they all died postopera-
tively. The authors admit that this procedure is long,
difficult, and technically demanding. Finally, Clagett et
al20 did not recommend this technique for very ill or
unstable patients, including patients with aortoenteric ero-
sion or fistula. Other authors have recommended in situ
prosthetic graft replacement for infrarenal aortic infection.
Although this may be a rational treatment option for local-
ized or circumscribed aortic infections caused by the
Staphylococcus epidermidis species, as reported by Towne et
al,22 it is not a reasonable option for diffusely infected
abdominal aortic prosthetic grafts.23 In an evaluation of
the Leicester experience (11 patients) with rifampycin-
bonded prostheses, Hayes et al24 recommend another
strategy for early infections (< 3 months) or when preop-
erative culture tests are positive for methicilline-resistant
Staphylococcus.
The use of fresh arterial allografts was abandoned 30
years ago because of late degenerative changes in the
grafts.25 However, improvement in organ-harvesting tech-
niques, allograft storage, and cryobiology techniques have
caused renewed interest in arterial allografts. In situ fresh
allograft replacement of infected infrarenal aortic pros-
thetic grafts has been reported by Kieffer et al14 and
resulted in a mortality rate of 12%. After a mean follow-up
period of 13.8 months (range, 1-42 months), 26% of the
patients had had pathogenic changes on their allografts,
and 9% of the patients required allograft-related reopera-
tion. More recently, in situ repair of aortobronchial, aor-
toesophageal, and aortoenteric fistulas with cryopreserved
aortic allografts has been reported by Vogt et al16 and
resulted in a mortality rate of 9%. After a mean follow-up
period of 14.3 months (range, 6-31 months), no cases of
allograft leakage, false aneurysm, or allograft stenosis
(except in 1 case) were observed. In our series, after a
mean follow-up period of 35.4 months, only 3 limited
Fig 3. Secondary patency rates with life-table analysis. Error bars
represent SEM.
aneurysmal dilatations occurred in 3 patent allografts,
requiring 3 reoperations that were not technically demand-
ing. This led to short operative times, short hospital stays,
and no perioperative deaths. With a longer follow-up
period, the incidence of degenerative changes in allografts
may be expected to increase, making close surveillance of
these allografts an obvious necessity. Our policy has been
to replace the aneurysmal segment of the allograft,
because, in our small series, aneurysmal allograft deterio-
ration was limited and restricted to the extra-abdominal
course of the allograft reconstruction.
We think that cryopreserved allografts offer several
advantages over fresh allografts. First, they allow better
management of available grafts and increase the availabil-
ity of suitable conduits for emergency use. This important
issue was applicable to the 13 patients in this series who
had emergency surgery. Second, blood compatibility can
be matched, and different types of vascular tissues can be
stored and made available for human leucocyte antigen
matching of donors and recipients before surgery. Third,
storage for a few months allows the allografts to be guar-
anteed safe from viral transmission by means of observing
changes in the humoral virology profile of recipients of
vital organs (liver, kidney, heart) from the same donor.
Cryopreservation is generally accepted as a useful
technique for the storage of vascular tissue. However,
optimal cryopreservation methods are still being debated.
Current cryopreservation protocols usually recommend
rate-controlled freezing and storage at very low tempera-
tures in liquid nitrogen vapor, mainly as a means of achiev-
ing long-term preservation of functional endothelial and
smooth muscle cells. In our opinion, preservation of cel-
lular viability, even if it is possible, is not necessary for
obtaining good large-caliber allograft performance.26
Moreover, because endothelial cells and smooth muscle
cells may elicit, although variably, an immune response,
preservation of the allograft’s cellular compound could,
theoretically and experimentally, have deleterious conse-
quences by mediating immunological arterial wall remod-
elings.27,28 More important, experimental and clinical data
strongly suggest that current cryopreservation protocols
probably result in making arterial allografts more brittle
and could induce early graft dilatation and rupture.29,30
Therefore, our unsophisticated cryopreservation method
(which has been successfully used to supply allogenic veins
and arteries for limb salvage in 57 patients who lack a suit-
able autologous saphenous vein5,6) was solely aimed at
preserving the extracellular matrix of the media that is not
known to bear allospecific transplantation antigens.31,32
Degenerative changes in the allograft are the major
drawback of this technique. Numerous studies on arterial
allograft rejection have identified the sequence of events in
arterial wall immune injury and response that progressively
leads to graft dilatation and rupture.27,28,33 Although
experimental data suggest that a low-maintenance dose of
cyclosporine provides effective immunosuppression, thus
preventing aneurysm formation,26,33 we, like others, hesi-
tate to administer a drug with serious potential adverse
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effects in elderly, critically ill patients. Future pharmaceu-
tical developments,34 modifications in allograft prepara-
tion,31 or both may reduce the problem of antigenicity
and reduce the late degenerative changes that have limited
the long-term effectiveness of allografts in the past.
CONCLUSION
Athough this study presents a small series of patients
with limited follow-up, in these patients, reconstruction
with a cryopreserved arterial allograft seemed to be a use-
ful option for treating one of the most dreaded vascular
complications. In major aortic infections and in patients
with severe underlying occlusive disease, the high opera-
tive mortality, reinfection, and amputation rates are still of
major concern and could be reduced with the use of these
allografts. At present, reconstruction with cryopreserved
arterial allografts should be regarded as a safe temporizing
maneuver to help eradicate infection and permit subse-
quent reconstructions with prosthetic material when nec-
essary.
REFERENCES
1. Curl G, Ricotta J. Total prosthetic graft excision and extra-anatomic
bypass. In: Calligaro K, Veith F, editors. Management of infected arte-
rial grafts. St Louis: Quality Medical Publishing; 1994. p. 82-94.
2. O’Hara PJ, Hertzer NR, Beven EG, Krajewski LP. Surgical manage-
ment of infected abdominal aortic grafts: review of a 25-year experi-
ence. J Vasc Surg 1986;3:725-31.
3. Donaldson RM, Ross DM. Homograft aortic root replacement for
complicated prosthetic valve endocarditis. Circulation 1984;70:178-81.
4. Zwischenberger JB, Shalaby TZ, Conti VR. Viable cryopreserved aor-
tic homograft for aortic valve endocarditis and annular abscesses. Ann
Thorac Surg 1989;48:365-9.
5. Leseche G, Penna C, Bouttier S, Joubert S, Andreassian B.
Femorodistal bypass using cryopreserved venous allografts for limb
salvage. Ann Vasc Surg 1997;11:230-6.
6. Castier Y, Leseche G, Palombi T, Petit MD, Cerceau O. Early experi-
ence with cryopreserved arterial allografts in below-knee revascular-
ization for limb salvage. Am J Surg 1999;177:197-202.
7. Menawat SS, Gloviczki P, Serry RD, Cherry KJ, Bower TC, Hallett
JW. Management of aortic graft-enteric fistulae. Eur J Vasc Endovasc
Surg 1997;14 Suppl A:74-81.
8. Ricotta JJ, Faggioli GL, Stella A, Curl GR, Peer R, Upson J, et al.
Total excision and extra-anatomic bypass for aortic graft infection. Am
J Surg 1991;162:145-9.
9. Sharp WJ, Hoballah JJ, Mohan CR, Kresowik TF, Martinasevic M,
Chalmers RT, et al. The management of the infected aortic prosthe-
sis: a current decade of experience. J Vasc Surg 1994;19:844-50.
10. Yeager RA, Taylor LM Jr, Moneta GL, Edwards JM, Nicoloff AD,
McConnell DB, et al. Improved results with conventional manage-
ment of infrarenal aortic infection. J Vasc Surg 1999;30:76-83.
11. Seeger JM, Pretus HA, Welborn MB, Ozaki CK, Flynn TC, Huber
TS. Long-term outcome after treatment of aortic graft infection with
staged extra-anatomic bypass grafting and aortic graft removal. J Vasc
Surg 2000;32:451-9.
12. Quinones-Baldrich WJ, Hernandez JJ, Moore WS. Long-term results
following surgical management of aortic graft infection. Arch Surg
1991;126:507-11.
13. Reilly LM, Ehrenfeld WK, Stoney RJ. Delayed aortic prosthetic
reconstruction after removal of an infected graft. Am J Surg 1984;
148:234-9.
14. Kieffer E, Bahnini A, Koskas F, Ruotolo C, Le Blevec D, Plissonnier
D. In situ allograft replacement of infected infrarenal aortic prosthetic
grafts: results in forty-three patients. J Vasc Surg 1993;17:349-55.
15. Koskas F, Goeau-Brissonniere O, Nicolas MH, Bacourt F, Kieffer E.
Arteries from human beings are less infectible by Staphylococcus
JOURNAL OF VASCULAR SURGERY
622 Lesèche et al October 2001
aureus than polytetrafluoroethylene in an aortic dog model. J Vasc
Surg 1996;23:472-6.
16. Vogt PR, Pfammatter T, Schlumpf R, Genoni M, Kunzli A, Candinas
D, et al. In situ repair of aortobronchial, aortoesophageal, and aor-
toenteric fistulas with cryopreserved aortic homografts. J Vasc Surg
1997;26:11-7.
17. Knosalla C, Weng Y, Yankah AC, Hofmeister J, Hetzer R. Using aor-
tic allograft material to treat mycotic aneurysms of the thoracic aorta.
Ann Thorac Surg 1996;61:1146-52.
18. Knosalla C, Goeau-Brissonniere O, Leflon V, Bruneval P, Eugene M,
Pechere JC, et al. Treatment of vascular graft infection by in situ
replacement with cryopreserved aortic allografts: an experimental
study. J Vasc Surg 1998;27:689-98.
19. Kuestner LM, Reilly LM, Jicha DL, Ehrenfeld WK, Goldstone J,
Stoney RJ. Secondary aortoenteric fistula: contemporary outcome
with use of extraanatomic bypass and infected graft excision. J Vasc
Surg 1995;21:184-95.
20. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral
reconstruction from superficial femoral-popliteal veins: feasibility and
durability. J Vasc Surg 1997;25:255-66.
21. Nevelsteen A, Lacroix H, Suy R. Autogenous reconstruction with the
lower extremity deep veins: an alternative treatment of prosthetic
infection after reconstructive surgery for aortoiliac disease. J Vasc Surg
1995;22:129-34.
22. Towne JB, Seabrook GR, Bandyk D, Freischlag JA, Edmiston CE. In
situ replacement of arterial prosthesis infected by bacterial biofilms:
long-term follow-up. J Vasc Surg 1994;19:226-33.
23. Robinson JA, Johansen K. Aortic sepsis: is there a role for in situ graft
reconstruction? J Vasc Surg 1991;13:677-82.
24. Hayes PD, Nasim A, London NJ, Sayers RD, Barrie WW, Bell PR, et
al. In situ replacement of infected aortic grafts with rifampicin-bonded
prostheses: the Leicester experience (1992 to 1998). J Vasc Surg
1999;30:92-8.
25. Szilagyi E, Rodriguez F, Smith R, Elliott J. Late fate of arterial allo-
grafts. Arch Surg 1970;101:721-33.
26. Vischjager M, Van Gulik TM, Van Marle J, Pfaffendorf M, Jacobs MJ.
Function of cryopreserved arterial allografts under immunosuppres-
sive protection with cyclosporine A. J Vasc Surg 1996;24:876-82.
27. Couvelard A, Leseche G, Scoazec JY, Groussard O. Human allograft
vein failure: immunohistochemical arguments supporting the involve-
ment of an immune-mediated mechanism. Hum Pathol 1995;26:
1313-20.
28. Plissonnier D, Nochy D, Poncet P, Mandet C, Hinglais N, Bariety J,
et al. Sequential immunological targeting of chronic experimental
arterial allograft. Transplantation 1995;60:414-24.
29. Lehalle B, Geschier C, Fieve G, Stoltz JF. Early rupture and degener-
ation of cryopreserved arterial allografts. J Vasc Surg 1997;25:751-2.
30. Hunt CJ, Song YC, Bateson EA, Pegg DE. Fractures in cryopreserved
arteries. Cryobiology 1994;31:506-15.
31. Allaire E, Guettier C, Bruneval P, Plissonnier D, Michel JB. Cell-free
arterial grafts: morphologic characteristics of aortic isografts, allo-
grafts, and xenografts in rats. J Vasc Surg 1994;19:446-56.
32. Salomon RN, Friedman GB, Callow AD, Payne DD, Libby P.
Cryopreserved aortic homografts contain viable smooth muscle cells
capable of expressing transplantation antigens. J Thorac Cardiovasc
Surg 1993;106:1173-80.
33. Schmitz-Rixen T, Megerman J, Colvin RB, Williams AM, Abbott
WM. Immunosuppressive treatment of aortic allografts. J Vasc Surg
1988;7:82-92.
34. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD,
Buchanan K, et al. Treatment with humanized monoclonal antibody
against CD154 prevents acute renal allograft rejection in nonhuman
primates. Nat Med 1999;5:686-93.
Submitted Jan 8, 2001; accepted Mar 21, 2001.
IMAGES AND REFLECTIONS
A new section in the Journal of Vascular Surgery, Images and Reflections, gives authors the opportunity 
for reflection by submitting creative writing (prose or poetry), photographs, artwork, and unique aspects of
medical history.
Submissions must be limited to one journal page. Please contact the Editor before submission.
